• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Steel Partners Holdings L.P. Issues Letter to InMode Ltd. Board of Directors Regarding the Company’s Persistent and Egregious Governance Failures

    7/16/26 4:10:00 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $INMD alert in real time by email

    Questions Whether Management is Steering Reported Results to Fit the CEO’s Lowball Bid

    Demands the Group Led by CEO Moshe Mizrahy Cure Its Disclosure Deficiencies

    Calls on the Board to Reschedule the Annual General Meeting to Allow Shareholders to Review Full Record and Bring Their Own Resolutions

    Steel Partners Holdings L.P. (together with its affiliates, "Steel"), a significant, long-standing shareholder of InMode Ltd. ("InMode" or the "Company") (NASDAQ:INMD), today issued a letter to the Board of Directors (the "Board") of the Company. The full text of the letter is below.

    July 16, 2026

    VIA ELECTRONIC MAIL

    InMode Ltd.

    Tavor Building, Sha’ar Yokneam

    P.O. Box 533

    Yokneam 2069206 Israel

    Attention: The Board of Directors

    Dear Members of the Board of Directors:

    As you know, Steel Partners Holdings L.P. (together with its affiliates, "Steel") is a significant, long-standing shareholder of InMode Ltd. We are writing to you to comment on recent events surrounding the Company and the actions taken by those in control.

    On July 13, the Company released preliminary second quarter revenue figures. In contrast to historical preliminary announcements, including the one issued just one quarter ago, this press release provided no margin or profitability figures of any kind. The press release then announced that there will be no earnings conference call, no webcast, and no investor meetings. The stated reason is the Special Committee’s ongoing "evaluation of strategic proposals."

    Shareholders are aware of a going-private offer from their own CEO, a superior competing offer from Steel, and are being asked to vote on directors at the upcoming Annual General Meeting (the "AGM"). At precisely the moment they need the most information, management has chosen to give them the least. Canceling all investor communication deprives shareholders of the ability to understand what is happening inside the Company and allows management to avoid answering for it. We do not believe that obfuscation is an effective investor relations strategy.

    The Timing of the Silence

    The Board should ask itself why management has gone quiet, and we believe the patterns observed over the past five months point to an uncomfortable answer.

    In late February and early March, Mr. Mizrahy bought roughly 800,000 shares of stock on the open market. On May 6, the Company guided to $73 to $78 million of 2026 non-GAAP income from operations. The stock did not respond.

    Five weeks later, on June 15, Mr. Mizrahy proposed to acquire the entire Company. In a public communication, he based his valuation on $65 million of adjusted EBITDA1, well below his own Company’s standing guidance. He claimed that figure was "based on publicly available information." We have seen no such information.

    When Mr. Mizrahy was buying shares, the Company’s disclosed results were meant to buoy the stock. Now that he wants to buy the entire Company at the lowest possible price, will reported earnings conveniently drift down toward his $65 million figure? Shareholders will find out on August 5. The Company just reiterated its full-year revenue guidance yet declined to say anything about profitability. If margins and operating income suddenly deteriorate toward the number in Mr. Mizrahy’s offer letter, the Board will need to explain why the CEO’s private number, which he disclosed only in his own personal communication, proved more accurate than the Company’s own public guidance.

    Mr. Mizrahy Is a Controlling Shareholder Under Israeli Law

    We believe Mr. Mizrahy is a controlling shareholder of InMode under Israeli law. His control does not rest on his share count alone. It flows from the combination of his ownership, his control of the Board, and his position as Chief Executive Officer and director.

    That status carries consequences. Israeli law imposes heightened requirements on any transaction between a company and its controlling shareholder, including approval by a genuinely independent committee and by a special majority of disinterested shareholders. It also raises serious questions about whether the Company has complied with these provisions throughout its history. These protections exist precisely because a controlling shareholder can shape the very process that is meant to check him.

    This background is directly relevant when assessing the composition and actions of the "Special Committee." Two of its purported independent members have financial and business ties to Mr. Mizrahy, as we detailed in our July 9 letter. A committee cannot negotiate at arm’s length with a man with whom multiple of its members share outside business ventures. Some of those outside ventures transact with InMode itself. Any process this committee runs, and any outcome it blesses, will be tainted from the start.

    The Disclosure Failures Continue

    Mr. Mizrahy and his group have repeatedly failed to disclose material information about their ownership that securities law requires. Steel has raised these deficiencies with the Company’s counsel over the past several months. The filings remain deficient today.

    Shareholders have a right to know the prices, quantities, and dates at which Mr. Mizrahy has bought and sold InMode’s stock while leading the Company. Other members of MN Business Strategy have disclosed almost nothing about their ownership positions, including their cost basis and dates of purchase. Basic questions about the group itself also remain unanswered. What are the relationships among these parties? Have they conducted business together outside of InMode? When was this plan hatched, and what impact will it have on the Company and its operations if this group does not ultimately succeed in acquiring the Company?

    Rescheduling the Annual General Meeting

    Shareholders will soon be asked to elect a director and approve Company resolutions at InMode’s Annual General Meeting on July 30, 2026. They deserve the opportunity to have all the facts before they vote – especially before being asked to support a purported "independent" director whose independence is clearly flawed. Shareholders must be provided with complete and corrected ownership disclosures from Mr. Mizrahy’s group, second quarter results with actual profitability figures and answers to the questions raised above. The AGM must be rescheduled until such time as the shareholders have the opportunity to consider all these facts, and to permit shareholders to nominate and elect truly independent directors.

    Every Company development over the past few months has deepened our concerns rather than eased them. We know that InMode has tremendous value that is not showing up in its current performance. The Company has gone silent, the disclosures remain deficient and a conflicted committee continues to sit in judgment of a conflicted deal. What’s more, the Board has not responded to our proposal to acquire the Company with any questions or requests for further details – which indicates to us that they may not be conducting a truly unbiased evaluation of the proposals in hand with the aim of securing maximum value for shareholders.  

    We reiterate each of the demands in our July 9 letter. If the Board remains on its current course, Steel will continue to pursue all available remedies before the U.S. Securities and Exchange Commission, the Israel Securities Authority and elsewhere to protect shareholders.

    Respectfully,

    Warren G. Lichtenstein

    Executive Chairman

    Steel Partners Holdings L.P.

    ____________________________

    1 The manner in which the Company calculates "non-GAAP income from operations" and the way that investors typically calculated adjusted EBITDA are identical.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260716392940/en/

    Longacre Square Partners

    Steel-INMD@Longacresquare.com

    Get the next $INMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INMD

    DatePrice TargetRatingAnalyst
    4/29/2025Buy → Neutral
    BTIG Research
    4/28/2025$22.00 → $16.00Outperform → Neutral
    Robert W. Baird
    10/17/2024$25.00Buy
    BTIG Research
    7/23/2024$21.00 → $19.00Buy → Hold
    Jefferies
    11/3/2023$52.00 → $24.00Buy → Neutral
    UBS
    10/13/2023$55.00 → $22.00Buy → Hold
    Canaccord Genuity
    3/29/2023$40.00Buy
    UBS
    2/17/2023Buy → Hold
    Needham
    More analyst ratings

    $INMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Moshe Itzkovich claimed ownership of 7,503 units of Ordinary Shares (SEC Form 3)

    3 - InMode Ltd. (0001742692) (Issuer)

    5/26/26 4:30:34 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    New insider Nass Shlomo claimed no ownership of stock in the company (SEC Form 3)

    3 - InMode Ltd. (0001742692) (Issuer)

    5/26/26 4:30:39 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by InMode Ltd.

    3 - InMode Ltd. (0001742692) (Issuer)

    3/18/26 7:09:10 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    InMode downgraded by BTIG Research

    BTIG Research downgraded InMode from Buy to Neutral

    4/29/25 8:06:22 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded InMode from Outperform to Neutral and set a new price target of $16.00 from $22.00 previously

    4/28/25 1:56:11 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BTIG Research initiated coverage on InMode with a new price target

    BTIG Research initiated coverage of InMode with a rating of Buy and set a new price target of $25.00

    10/17/24 7:41:34 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    SEC Filings

    View All

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    7/20/26 4:01:15 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    7/13/26 9:00:03 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    7/10/26 6:59:57 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Steel Partners Holdings L.P. Issues Letter to InMode Ltd. Board of Directors Regarding the Company’s Persistent and Egregious Governance Failures

    Questions Whether Management is Steering Reported Results to Fit the CEO’s Lowball Bid Demands the Group Led by CEO Moshe Mizrahy Cure Its Disclosure Deficiencies Calls on the Board to Reschedule the Annual General Meeting to Allow Shareholders to Review Full Record and Bring Their Own Resolutions Steel Partners Holdings L.P. (together with its affiliates, "Steel"), a significant, long-standing shareholder of InMode Ltd. ("InMode" or the "Company") (NASDAQ:INMD), today issued a letter to the Board of Directors (the "Board") of the Company. The full text of the letter is below. July 16, 2026 VIA ELECTRONIC MAIL InMode Ltd. Tavor Building, Sha’ar Yokneam P.O. Box 533 Yokneam 20692

    7/16/26 4:10:00 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode to Report Second Quarter 2026 Financial Results on August 5, 2026, Expects Q2 Revenue Between $95.2M-$95.4M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

    YOKNEAM, Israel, July 13, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the second quarter of 2026 before the Nasdaq market opens on Wednesday, August 5, 2026. InMode is currently finalizing its financial results for the second quarter of 2026. While complete financial information and operating data are not yet available, set forth below are certain preliminary results such period, subject to final adjustments and other developments that may arise between now and the time such financial results a

    7/13/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode Confirms Receipt of Unsolicited Proposal

    YOKNEAM, Israel, July 10, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) (the "Company") confirmed that its Board of Directors (the "Board") has received the unsolicited letter and acquisition proposal from Steel Partners Holdings L.P. dated July 9, 2026. The Special Committee comprised solely of the independent directors of the Board (the "Special Committee"), together with its legal and financial advisors, will carefully review the proposal consistent with its fiduciary duties.The Special Committee remains committed to acting in the best interests of all shareholders. The Special Committee does not intend to comment further at this time.About InMode Ltd.The Company is a leading global prov

    7/10/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Leadership Updates

    Live Leadership Updates

    View All

    After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

    Conexeu Sciences just 3D-bioprinted a new tissue matrix to one of the most respected regenerative medicine institutes in the world. For investors watching how breast reconstruction — and the wider field of tissue regeneration — evolves, the next 18 months matter. NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary — For more than fifty years, breast reconstruction has mostly meant one thing: replacement. A silicone shell, filled with gel, designed to restore shape and volume, none of them designed to regenerate the breast's own living tissue. That gap has consequences. Roughly two-thirds of the more than 100,000 women in the United States who undergo a mastectomy ea

    5/27/26 9:00:00 AM ET
    $ESTA
    $INMD
    $PCRX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Biotechnology: Pharmaceutical Preparations

    InMode Appoints Dr. Shlomo Nass as Chairman of the Board and Moshik Itzkovich as Chief Financial Officer

    YOKNEAM, Israel, May 20, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode" or the "Company"), a leading global provider of innovative medical technologies, today announced the appointment of Dr. Shlomo Nass as Chairman of the Company's Board of Directors (the "Board") and Moshik Itzkovich as Chief Financial Officer, effective immediately. Dr. Nass succeeds Dr. Michael Anghel, who retired earlier this month, and will lead the Board in supporting the Company's long-term strategic growth and governance priorities. Dr. Nass brings decades of expertise in corporate law, accoun

    5/20/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode Appoints Michael Dennison as President of North America

    IRVINE, Calif., Nov. 3, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America.  Dennison has held nearly every sales position in the aesthetic medical device industry, consistently producing at the highest level in each. With close to a decade of leadership experience at InMode, Dennison has advanced through roles from District Sales Manager to Vice President of Sales, driving national revenue growth, expanding market shar

    11/3/25 8:05:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    SC 13G/A - InMode Ltd. (0001742692) (Subject)

    2/13/24 4:31:18 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    SC 13G/A - InMode Ltd. (0001742692) (Subject)

    2/13/24 4:25:40 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by InMode Ltd.

    SC 13G - InMode Ltd. (0001742692) (Subject)

    2/6/24 9:36:39 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Financials

    Live finance-specific insights

    View All

    Steel Partners Holdings L.P. Issues Letter to InMode Ltd. Board of Directors Regarding the Company’s Persistent and Egregious Governance Failures

    Questions Whether Management is Steering Reported Results to Fit the CEO’s Lowball Bid Demands the Group Led by CEO Moshe Mizrahy Cure Its Disclosure Deficiencies Calls on the Board to Reschedule the Annual General Meeting to Allow Shareholders to Review Full Record and Bring Their Own Resolutions Steel Partners Holdings L.P. (together with its affiliates, "Steel"), a significant, long-standing shareholder of InMode Ltd. ("InMode" or the "Company") (NASDAQ:INMD), today issued a letter to the Board of Directors (the "Board") of the Company. The full text of the letter is below. July 16, 2026 VIA ELECTRONIC MAIL InMode Ltd. Tavor Building, Sha’ar Yokneam P.O. Box 533 Yokneam 20692

    7/16/26 4:10:00 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode to Report Second Quarter 2026 Financial Results on August 5, 2026, Expects Q2 Revenue Between $95.2M-$95.4M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

    YOKNEAM, Israel, July 13, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the second quarter of 2026 before the Nasdaq market opens on Wednesday, August 5, 2026. InMode is currently finalizing its financial results for the second quarter of 2026. While complete financial information and operating data are not yet available, set forth below are certain preliminary results such period, subject to final adjustments and other developments that may arise between now and the time such financial results a

    7/13/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode Reports First Quarter 2026 Financial Results: Quarterly GAAP Revenue of $82 Million, Represents 5% Year-Over-Year Increase

    YOKNEAM, Israel, May 6, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter of 2026. First Quarter 2026 Highlights:●  Quarterly GAAP revenues of $82.0 million, compared to $77.9 million in the first quarter of 2025.●  Quarterly revenues from consumables and service of $21.4 million, an increase of 6% compared to the first quarter of 2025.●  GAAP operating income of $10.1 million, *non-GAAP operating income of $14.0 million.●  Total cash po

    5/6/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care